Jennifer Lynn Leddon, MD, PhD

MD/PhD: University of Cincinnati

BS: University of Alabama Birmingham,

American Board of Internal Medicine (Certification Date: 08-16-2019 )

American Board of Internal Medicine (Medical Oncology) (Certification Date: 11-08-2023 )

Lung Cancer

Hematology and Oncology

Medical Oncology

Oncology

Hematology

Thoracic and Lumbar Spine Disorders

Internal Medicine

Medical Oncology

Grant: #CF33-hNIS-002 04-01-2022 -03-31-2025 Imugene Limited A Phase I, Dose Escalation Safety and Tolerability Study of VAXINIA (CF33-hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination with Pembrolizumab in Adult Patients Role:PI 721197.85 Hold Level:Industry

Grant: #CF33-hNIS-002 04-01-2022 -03-31-2025 Imugene Limited A Phase I, Dose Escalation Safety and Tolerability Study of VAXINIA (CF33-hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination with Pembrolizumab in Adult Patients Role:PI 721197.85 Hold Level:Industry

Grant: #NG-641-03 Investigators:Leddon, Jennifer 04-26-2023 -04-25-2026 Premier Research International LLC A multicentre, open-label, non-randomized, phase 1a/1b study of NG-641, a tumour-selective and transgene-expressing adenoviral vector, in combination with nivolumab in patients with metastatic or ad Role:PI 678371.74 Hold Level:Industry

Grant: #TAV0412 Investigators:Leddon, Jennifer 06-27-2023 -06-27-2026 Tavotek Biotherapeutics A 2-Part Open-Label Phase I Study of TAVO412 in Patients with Advanced or Metastatic Solid Tumors who progressed on prior approved standard of care therapy Role:PI 474391.93 Hold Level:Industry

Grant: #DF9001-001 Investigators:Leddon, Jennifer 08-24-2023 -08-24-2026 Dragonfly Therapeutics A phase 1/2 to InvestigateDF9001 in Patients With Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors, and Expansion in Selected Indications Role:PI 1492048.01 Hold Level:Industry

Grant: #PRESERVE-003 Investigators:Leddon, Jennifer 11-15-2023 -11-15-2026 OncoC4, Inc. Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors Role:PI 461365.32 Hold Level:Industry

Grant: #CA001-050 Investigators:Leddon, Jennifer; Riaz, Muhammad Kashif 09-01-2021 -08-31-2024 Bristol-Myers Squibb Co. A Randomized, Open-label Phase 2 Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer Role:PI 532748.15 Active Level:Industry

Grant: #CF33-CD19-101 Investigators:Leddon, Jennifer 02-26-2024 -02-26-2027 Imugene Limited A Phase I, Dose Escalation and Dose Expansion, Safety and Tolerability Study of onCARlytics (CF33-CD19), Administered Intravenously or Intratumorally in Combination with Blinatumomab in Adults with Ad Role:PI 1048337.24 Hold Level:Industry

Grant: #V940-002 Investigators:Leddon, Jennifer 06-12-2024 -06-12-2027 Merck Sharp & Dohme LLC A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants Role:PI 3971754.65 Active Level:Industry

Grant: #GMO221215; PO No.0000002543; Prime Grant No. G-18-100 Investigators:Leddon, Jennifer; Riaz, Muhammad Kashif 01-01-2022 -12-31-2024 Gateway for Cancer Research A Phase 2 Single-Center Pharmacodynamic Study of TVB-2640 in KRAS Mutant Non-Small Cell Lung Carcinomas Role:PI 30137.00 Active Level:Non Profit

Grant: #CA224-1093 Investigators:Leddon, Jennifer 12-23-2024 -12-23-2027 Bristol-Myers Squibb Co. A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Stage IV Role:PI 2533843.67 Hold Level:Industry

Grant: #TV56278-ONC-10203 Investigators:Leddon, Jennifer 02-24-2025 -02-24-2028 Teva Pharmaceuticals, Inc A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination with Pembrolizumab, in Participan Role:PI 1801839.98 Hold Level:Industry

Grant: #D702BC00001 ARTEMIDE-Lung02 Investigators:Leddon, Jennifer 03-05-2025 -03-05-2028 AstraZeneca Pharmaceuticals LP Site for A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients wit Role:PI 1128464.45 Hold Level:Industry

Grant: #22615 SOHO-02 Investigators:Leddon, Jennifer 03-10-2025 -03-10-2028 Bayer AG A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in Role:PI 1157031.78 Hold Level:Industry

Grant: #BNT327-06 Investigators:Leddon, Jennifer 05-12-2025 -05-12-2028 BioNTech SE A Phase II/III, multisite, randomized master protocol for a global trials of BNT327 in combination with chemotherapy and other investigational agents in first-line non-small cell lung cancer Role:PI 5261427.71 Hold Level:Industry

Grant: #KB707-01 Investigators:Leddon, Jennifer 05-09-2025 -05-09-2028 GOG Foundation, Inc. A Phase 1/2, Open-Label, Multicenter, Dose Escalation and Expansion Study of KB707 in Subjects with Locally Advanced or Metastatic Solid Tumor Malignancies Role:PI 461810.82 Hold Level:Non Profit

Investigators:Leddon, Jennifer 07-25-2025 -07-25-2028 Krystal Biotech A Phase 1/2 Study of Inhaled KB707 in Patients with Advanced Solid Tumor Malignancies Affecting the Lungs Role:PI 291623.51 Hold Level:Industry

Published Abstracts

Leddon, J.L., Chen, C.Y., Currier, M.A., Wang, P.Y., Jung, F.A., Denton, N.L., Cripe, K.M., Haworth, K.B., Arnold, M.A., Gross, A.C. and Eubank, T.D. (2015) Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity. [Abstract]Molecular therapy oncolytics, 1 ,14010

Currier, M.A., Eshun, F.K., Sholl, A., Chernoguz, A., Crawford, K., Divanovic, S., Boon, L., Goins, W.F., Frischer, J.S., Collins, M.H. and Leddon, J.L. (2013) VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells. [Abstract]Molecular Therapy, 21(5) ,1014

Browne, A.W., Leddon, J.L., Currier, M.A., Williams, J.P., Frischer, J.S., Collins, M.H., Ahn, C.H. and Cripe, T.P. (2011) Cancer screening by systemic administration of a gene delivery vector encoding tumor-selective secretable biomarker expression. [Abstract]PloS one, 6(5) ,19530